SLC5A2 and heart failure: Recent advances in pharmacological therapies for heart failure (HF), such as sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, have contributed to reducing cardiovascular events across a broad range of left ventricular ejection fractions [30, 31].